153 related articles for article (PubMed ID: 25649906)
21. Statin use and risk of prostate cancer in a population of men who underwent biopsy.
Tan N; Klein EA; Li J; Moussa AS; Jones JS
J Urol; 2011 Jul; 186(1):86-90. PubMed ID: 21571344
[TBL] [Abstract][Full Text] [Related]
22. Use of low free to total PSA ratio in prostate cancer screening: detection rates, clinical and pathological findings in Brazilian men with serum PSA levels <4.0 ng/mL.
Faria EF; Carvalhal GF; dos Reis RB; Tobias-Machado M; Vieira RA; Reis LO; Nogueira L; Machado RD; Freitas CH; Magnabosco WJ; Mauad EC; Carvalho AL
BJU Int; 2012 Dec; 110(11 Pt B):E653-7. PubMed ID: 22892057
[TBL] [Abstract][Full Text] [Related]
23. The prognostic value of ribonucleotide reductase small subunit M2 in predicting recurrence for prostate cancers.
Huang Y; Liu X; Wang YH; Yeh SD; Chen CL; Nelson RA; Chu P; Wilson T; Yen Y
Urol Oncol; 2014 Jan; 32(1):51.e9-19. PubMed ID: 24360663
[TBL] [Abstract][Full Text] [Related]
24. Comparison of the efficacies of five different statins on inhibition of human saphenous vein smooth muscle cell proliferation and invasion.
Turner NA; Midgley L; O'Regan DJ; Porter KE
J Cardiovasc Pharmacol; 2007 Oct; 50(4):458-61. PubMed ID: 18049315
[TBL] [Abstract][Full Text] [Related]
25. Comparative effects of high and low-dose simvastatin on prostate epithelial cells: the role of LDL.
Murtola TJ; Syvälä H; Pennanen P; Bläuer M; Solakivi T; Ylikomi T; Tammela TL
Eur J Pharmacol; 2011 Dec; 673(1-3):96-100. PubMed ID: 22040920
[TBL] [Abstract][Full Text] [Related]
26. Cholesterol-lowering drugs and prostate cancer risk: a population-based case-control study.
Murtola TJ; Tammela TL; Lahtela J; Auvinen A
Cancer Epidemiol Biomarkers Prev; 2007 Nov; 16(11):2226-32. PubMed ID: 18006910
[TBL] [Abstract][Full Text] [Related]
27. The effects of different types of statins on proliferation and migration of HGF-induced Human Umbilical Vein Endothelial Cells (HUVECs).
Burgazli KM; Bui KL; Mericliler M; Albayrak AT; Parahuleva M; Erdogan A
Eur Rev Med Pharmacol Sci; 2013 Nov; 17(21):2874-83. PubMed ID: 24254555
[TBL] [Abstract][Full Text] [Related]
28. Prostate-specific antigen and long-term prediction of prostate cancer incidence and mortality in the general population.
Orsted DD; Nordestgaard BG; Jensen GB; Schnohr P; Bojesen SE
Eur Urol; 2012 May; 61(5):865-74. PubMed ID: 22104593
[TBL] [Abstract][Full Text] [Related]
29. Use of statins and prostate cancer recurrence among patients treated with radical prostatectomy.
Chao C; Jacobsen SJ; Xu L; Wallner LP; Porter KR; Williams SG
BJU Int; 2013 May; 111(6):954-62. PubMed ID: 23464862
[TBL] [Abstract][Full Text] [Related]
30. Risk of repeat biopsy and prostate cancer detection after an initial extended negative biopsy: longitudinal follow-up from a prospective trial.
Ploussard G; Nicolaiew N; Marchand C; Terry S; Allory Y; Vacherot F; Abbou CC; Salomon L; de la Taille A
BJU Int; 2013 May; 111(6):988-96. PubMed ID: 23452046
[TBL] [Abstract][Full Text] [Related]
31. Prostate cancer diagnosis among men with isolated high-grade intraepithelial neoplasia enrolled onto a 3-year prospective phase III clinical trial of oral toremifene.
Taneja SS; Morton R; Barnette G; Sieber P; Hancock ML; Steiner M
J Clin Oncol; 2013 Feb; 31(5):523-9. PubMed ID: 23295793
[TBL] [Abstract][Full Text] [Related]
32. Cholesterol, cholesterol-lowering agents/statins, and urologic disease: Part V--Statins versus aspirin for primary prevention, and the winner is...?
Moyad MA; Merrick GS
Urol Nurs; 2007 Apr; 27(2):166-8. PubMed ID: 17494461
[TBL] [Abstract][Full Text] [Related]
33. Association between nonsteroidal anti-inflammatory drugs and prostate cancer occurrence.
Dasgupta K; Di Cesar D; Ghosn J; Rajan R; Mahmud S; Rahme E
Cancer J; 2006; 12(2):130-5. PubMed ID: 16630404
[TBL] [Abstract][Full Text] [Related]
34. Prostate cancer risk in men with baseline history of coronary artery disease: results from the REDUCE Study.
Thomas JA; Gerber L; Bañez LL; Moreira DM; Rittmaster RS; Andriole GL; Freedland SJ
Cancer Epidemiol Biomarkers Prev; 2012 Apr; 21(4):576-81. PubMed ID: 22315364
[TBL] [Abstract][Full Text] [Related]
35. Statins may increase the risk of being diagnosed with prostate cancer.
Brassetti A; Tedesco F; Cacciatore L; Prata F; Ragusa A; Iannuzzi A; Lombardo R; Tema G; Cicione A; Tubaro A; Simone G; DE Nunzio C
Minerva Urol Nephrol; 2024 Feb; 76(1):74-80. PubMed ID: 37795695
[TBL] [Abstract][Full Text] [Related]
36. Statins effect on smooth muscle cell proliferation.
Bellosta S; Arnaboldi L; Gerosa L; Canavesi M; Parente R; Baetta R; Paoletti R; Corsini A
Semin Vasc Med; 2004 Nov; 4(4):347-56. PubMed ID: 15861311
[TBL] [Abstract][Full Text] [Related]
37. Zoledronic acid in combination with serine/threonine phosphatase inhibitors induces enhanced cytotoxicity and apoptosis in hormone-refractory prostate cancer cell lines by decreasing the activities of PP1 and PP2A.
Cirak Y; Varol U; Atmaca H; Kisim A; Sezgin C; Karabulut B; Uzunoglu S; Uslu R; Karaca B
BJU Int; 2012 Dec; 110(11 Pt C):E1147-54. PubMed ID: 22882676
[TBL] [Abstract][Full Text] [Related]
38. The influence of statin medications on prostate-specific antigen levels.
Hamilton RJ; Goldberg KC; Platz EA; Freedland SJ
J Natl Cancer Inst; 2008 Nov; 100(21):1511-8. PubMed ID: 18957682
[TBL] [Abstract][Full Text] [Related]
39. Statins and prostate cancer: molecular and clinical aspects.
Papadopoulos G; Delakas D; Nakopoulou L; Kassimatis T
Eur J Cancer; 2011 Apr; 47(6):819-30. PubMed ID: 21354784
[TBL] [Abstract][Full Text] [Related]
40. Influence of HMG-CoA reductase inhibitors on leptin-induced endothelial cell proliferation, migration, and capillary-like tube formation.
Burgazli KM; Stein NI; Mericliler M; Parahuleva M; Erdogan A
Postgrad Med; 2014 May; 126(3):231-8. PubMed ID: 24918807
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
